Evotec Results Presentation Deck

evotec At equity investments (share ≥ 20% or significant influence) facio therapies Eternygen Equity participation Metabolic disorders Initiated 2016 Carrick PAGE 30 therapeutics Equity participation Innovative pathways in oncology Initiated 2016 Topas Therapeutics Spin-off Nanoparticle- based therapeutics Minority Shareholdings (share < 20%) Initiated 2016 Exscientia Equity participation Al for auto- mated drug design Initiated 2017 Equity participation FSHD Growing portfolio with operational synergies EVOequity overview Initiated 2017 FORGE Therapeutics Equity participation Targeting metallo- enzymes Initiated 2017 AUTOBAHN LABS Equity (in-kind) Cross therapeutic areas Initiated 2019 FIBROCOR Equity participation Fibrosis partnership Initiated 2017 BREAKPOINT THERAPEUTICS Spin-off DNA damage response Initiated 2019 Aeovian PHARMACEUTICALS Initiated 2019 Equity participation Women's health celmatix® Initiated 2019 Equity Equity participation participation Inflammatory disease Immunitas THERAPEUTICS Oncology / Biologics Initiated 2019 CUREXSYS PURE TO CURE Equity participation Cross therapeutic areas Initiated 2020 BLACKSMITH Medicines DARK BLUE Initiated 2019 THERAPEUTICS Spin-off (LAB282) Oncology Initiated 2020 LEON ENABLING NANO NOW Equity Equity participation participation Oncology Formulation nanotech- nologies Initiated 2020 Equity participation Failsafe cloaking for cell therapies mission BIOCAPITAL Venture fund Invests into early-stage life science companies a Initiated 2020 panCELLa Initiated 2020 Cajal Neuroscience Equity participation Neuro-science Initiated 2020 QUANTR !!~ and Therapeutics Equity participation partnership Oncology Initiated 2020 oxvax Equity participation Immuno- oncology Initiated 2021 Joint Venture New NephThera Joint Venture with Vifor Pharma Nephrology Initiated 2019 ARGOBIO STUDIO Equity participation Cros therapeutic areas Initiated 2021 New

View entire presentation